From Yahoo Finance: 2025-04-02 08:19:00

Renaissance Investment Management released its Q4 2024 Small Cap Growth Strategy investor letter, showing a 15.2% yearly return. The portfolio outperformed the Russell 2000 Growth Index in the fourth quarter, with positive returns driven by stock selection in Information Technology and Health Care. For more details, check its top five holdings.

In Q4 2024, Renaissance Investment Management highlighted Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) in its investor letter. CPRX, a biopharma company, saw a 9.27% one-month return and 54.42% gain over 52 weeks. On April 1, 2025, CPRX stock closed at $23.92 per share with a market cap of $2.905 billion.

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) was a new position added by Renaissance Investment Management in Q4 2024. The company focuses on rare orphan drugs targeting neurological and neuromuscular disorders, with a strategy to acquire additional drugs for long-term growth opportunities in the orphan drug market.

Our database shows 35 hedge fund portfolios held Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) at the end of Q4 2024. CPRX reported $491.7 million in revenues in 2024, a 23.5% increase from 2023. While CPRX has potential, we believe AI stocks offer greater returns in a shorter timeframe. Check out our report on the cheapest AI stock for promising investment opportunities.

Read more: What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice?